期刊文献+

58例脑胶质瘤术后同步放化疗的疗效观察 被引量:2

原文传递
导出
摘要 目的:评价脑胶质瘤术后行同步放化疗的疗效。方法:58例脑胶质瘤患者术后随机分为放疗组29例及放疗+化疗组29例。放疗组术后仅行三维适形放疗,总剂量DT 60 Gy/4~6周;放疗+化疗组给予同样三维适形放疗,并同步于术后10~15 d(平均12 d)开始行超选介入动脉灌注尼莫司汀化疗,每4周1次,每次2.5 mg.kg^(-1),共进行4~6次结束。结果:放疗+化疗组总有效率(肿瘤消失+肿瘤明显缩小)75.9%(22/29例),1年生存率(75.86%),2年生存率(51.72%),与放疗组相比差异有统计学意义(P<0.05);结论:脑胶质瘤术后行同步放化疗,对脑胶质瘤有明显疗效。
出处 《中国临床神经科学》 2010年第4期419-422,共4页 Chinese Journal of Clinical Neurosciences
  • 相关文献

参考文献12

二级参考文献41

  • 1顾科,张军宁.脑胶质瘤放化疗研究进展[J].实用癌症杂志,2005,20(6):665-667. 被引量:13
  • 2Osoba D,Brada M,Yung WK.Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme [J].J Clin Oncol,2000,18 (8):1481. 被引量:1
  • 3Zunkeler B,Carson RE,Olson J,et al.Quantification and pharmacokinetics of blood-brain disruption in humans [J].J Neurosurgery,1996,85 (7) :1056. 被引量:1
  • 4Weyebrock A,Walbridge S,Pluta RM,et al.Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas[J].J Neurosurg,2003,99 (4):728. 被引量:1
  • 5Prados MD,ScholdSC JR,Fine HA,et al.A randomized doublebline placebo-controlled phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma [J].Neuro Oncol,2003,5 (2):96. 被引量:1
  • 6Brandes AA,Vastola F,Basso U,et al.A prospective study on glioblastoma in the elderly[J].Cancer,2003,97(3):657. 被引量:1
  • 7Brandes AA,Turazzi S,Basso U,et al.A multidrug combination designed for reversing resistance to BCNU in glioblastoma [J].Neurology,2002,58 (12):1759. 被引量:1
  • 8Central Brain Tumor Registry of the United States(CBTRUS).Statistical report:primary brain tumors in the United States,1997-2001.Hinsdale IL[M].Central Brain Tumor Registry of the United States,2004. 被引量:1
  • 9Buckner JC,Gesme D Jr,O,fallon JR,et al.Phase Ⅱ trial of procarbazine,lomustine,and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma:efficacy and associations with chromosomal abnormalities[J].J Clin Oncol,2003,21(1) :251. 被引量:1
  • 10Eyre HJ,Crowley JJ,Townsend JJ,et al.A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas:a southwestern oncology group study [J].J Neurosurg,1993,78(3) :909. 被引量:1

共引文献57

同被引文献17

  • 1Roguin A,Goldstein J,Bar O.Brain tumours among interventional cardiologists:a cause for alarm.report of four new cases from two cities and a review of the literature[J].Euro Intervention,2012,7:1081-1086. 被引量:1
  • 2Saitta L,Heese O,Frster AF,et al.Signal intensity in T2'magnetic resonance imaging is related to brain glioma grade[J].Eur Radiol,2011,21:1068-1076. 被引量:1
  • 3Boockvar JA,Tsiouris AJ,Hofstetter CP,et al.Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma[J].J Neurosurg,2011,114:624-632. 被引量:1
  • 4Briganti C,Sestieri C,Mattei PA,et al.Reorganization of functional connectivity of the language network in patients with brain gliomas[J].American J Neuroradiology,2012,33:1983-1990. 被引量:1
  • 5Burkhardt JK,Riina H,Shin BJ,et al.Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma:progression-free survival and overall survival[J].World Neurosurgery,2012,77:130-134. 被引量:1
  • 6Price SJ,Green HAL,Dean AF,et al.Correlation of MR relative cerebral blood volume measurements with cellular density and proliferation in high-grade gliomas:an image-guided biopsy study[J].American J Neuroradiology,2011,32:501-506. 被引量:1
  • 7Wang J, Sai K, Chen FR, et al. miR 181b modulates glioma cell sensitivity to temozolomide by targeting MEK1[J]. Cancer Chemother Pharmacol, 2013,5(10):1 684-1 689. 被引量:1
  • 8Yust Katz S, Liu D, Yuan Y, et al. Phase 1/lb study of lona- farnib and temozolomide in patients with recurrent or temozolo mide refractory glioblastoma[J]. Cancer, 2013, 4 ( 30 ) : 149- 153. 被引量:1
  • 9Hart MG, Garside R, Rogers G, et al. Temozolomide for high grade glioma[J]. Cochrane Database Syst Rev, 2013,4 (13) : 1 284-1 289. 被引量:1
  • 10Quann K, Gonzales DM, Mercier I, et al. Caveolin-1 is a neg- ative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide[J]. Cell Cycle, 2013, 12(10):18- 23. 被引量:1

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部